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Abstract 
Background 
Migraine is a common episodic brain disorder characterized by recurrent attacks of severe 
unilateral headache and additional neurological symptoms. Two main migraine types can be 
distinguished based on the presence of aura symptoms that can accompany the headache: 
migraine with aura and migraine without aura. Multiple genetic and environmental factors 
confer disease susceptibility. Recent genome-wide association studies (GWAS) indicate that 
migraine susceptibility genes are involved in various pathways, including neurotransmission, 
which have already been implicated in genetic studies of monogenic familial hemiplegic 
migraine, a subtype of migraine with aura. 
 
Methods 
To further explore the genetic background of migraine, we performed a gene set analysis of 
migraine GWAS data of 4,954 clinic-based patients with migraine, as well as 13,390 
controls. Curated sets of synaptic genes and sets of genes predominantly expressed in three 
glial cell types (astrocytes, microglia, and oligodendrocytes) were investigated. 
 
Discussion 
Our results show that gene sets containing astrocyte- and oligodendrocyte-related genes are 
associated with migraine; which is especially true for gene sets involved in protein 
modification and signal transduction. Observed differences between migraine with aura and 
migraine without aura, indicate that both migraine types, at least in part, seem to have a 
different genetic background. 
 
Key words: Migraine, GWAS, pathway analysis, astrocytes, oligodendrocytes, synapse 
3 
 
Introduction 
Migraine is a common brain disorder affecting 15% of the population and characterized by 
recurrent attacks of severe, often unilateral headache associated with additional neurological 
symptoms such as nausea, vomiting and an increased sensitivity to light and sound (1). The 
presence of an aura accompanying the headache phase, consisting of transient neurological 
symptoms that are usually visual in nature, distinguishes between migraine with aura and 
migraine without aura.  
 
Genome-wide association studies (GWAS), which have become a widely used approach to 
study the genetic background of common disorders, already yielded thirteen genome-wide 
significant loci for migraine (2-5). Several of the migraine candidate genes (i.e. MTDH, 
LRP1, PRDM16, MEF2D, ASTN2, PHACTR1, FHL5, MMP16) that have been brought up by 
these GWAS loci can be linked to (glutamatergic) neurotransmission (2-5). This seems in line 
with previous genetic findings in familial hemiplegic migraine, a monogenic subtype of 
migraine with aura (1), that revealed that all three causal genes identified so far (CACNA1A, 
ATP1A2 and SCN1A) play an important role in glutamatergic neurotransmission (6).  
 
All currently known migraine GWAS loci combined explain only a minor fraction of the 
genetic heritability that has been estimated at 50% in twin studies (7), which is not different 
from GWAS findings in other common disorders (8). Part of the missing heritability may be 
explained by variants that do not reach the threshold for genome-wide significance, which is 
not unexpected given the small effect sizes that GWAS hits have and the large samples sizes 
that are needed to detect them. Such yet unidentified variants might be enriched in genes that 
play a role in disease-related pathways. Therefore, additional pathophysiological insights may 
be obtained by investigating GWAS data for specific disease-relevant gene sets. Here, we 
4 
 
used three expert-curated glial cell-related gene lists (i.e. astrocyte, oligodendrocyte and 
microglia cell type-related gene lists) (9), and a synaptic gene list (10) to study the role of 
genes involved in synaptic mechanisms and glial cells in common migraine. The four gene 
lists were subdivided into functional gene sets and investigated for association with migraine. 
This approach has been applied successfully in e.g. schizophrenia, thus identifying a role for 
synaptic genes (12) as well as specific astrocyte and oligodendrocyte functions (9). For the 
analysis, we used GWAS data of 13,588 control individuals and 5,037 migraine patients 
(2,733 patients with migraine with aura and 2,304 patients with migraine without aura) that 
were recruited via specialized headache clinics (2,5). We used clinic-based migraine GWAS 
cohorts, as phenotypic information is more complete and accurate than in population-based 
cohorts. This might reduce the clinical and genetic heterogeneity within the cohorts, thereby 
increasing the likelihood of identifying associations with migraine. Our gene set analyses 
results indicated a role for astrocyte- and oligodendrocyte-specific genes in migraine 
pathophysiology with a different contribution in both migraine types.  
 
Material and Methods 
Subjects 
In this study we investigated genetic data of 5,037 migraine cases (2,733 patients with 
migraine with aura and 2,304 patients with migraine without aura) and 13,588 controls that 
were part of two previously published clinic-based GWA studies (2,5). Patients were 
collected via specialized headache centers within Europe (the Netherlands, Finland, and 
Germany). Migraine diagnoses were established using a combination of questionnaires and 
individual interviews, based on the ICHD-IIIbeta guidelines (1). 
 
Genotyping and quality control 
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Patient and control samples were genotyped using Illumina arrays, except for the German 
control cohort that was used for the migraine without aura GWAS, which was genotyped 
partly using Illumina and partly using Affymetrix arrays (for details see Anttila et al. (2) and 
Freilinger et al. (5)). Sample and genotype quality controls were performed specifically for 
this study using the raw genotyping data of the discovery cohorts of Anttila et al. (2) and 
Freilinger et al. (5), using the protocol described in Anderson et al. (11). In short, samples 
were removed in case of non-European ancestry, as measured with principal components 
analysis with EIGENSTRAT, sex discrepancies between genotypic and phenotypic data, 
missingness (> 3% of SNPs), outlying heterozygosity rate (> 5SD) and relatedness (IBS > 
0.125). Samples were also removed if no valid principal components for stratification 
correction could be computed. We retained 4,954 migraine cases and 13,390 controls after 
QC (Table 1). SNPs were removed from the analysis in case of: (i) a minor allele frequency < 
1%; (ii) a deviation from Hardy-Weinberg equilibrium (P < 10-5) in cases or controls; (iii) 
missing data for a SNP in > 3% of the individuals; (iv) a significantly different missing data 
rate between cases and controls (P < 10-5); or (v) a non-unique genomic localization of SNPs.  
 
Gene lists and gene sets 
Four published, expert-curated gene lists, i.e. astrocytic, oligodendrocytic, microglia, and 
synaptic, were used for the analysis (9,10). In brief, the glial gene lists (astrocytic, 
oligodendrocytic, microglial) contain genes with enriched expression in at least one of these 
cell types based on: (i) microarray data of FACS-sorted oligodendrocytes, astrocytes and 
microglia from developing and adult mouse brain (12); (ii) genes that co-express with cell 
type markers in microarray data of human brain tissue (13,14); (iii) genes that are 
differentially expressed in microglia cell cultures after an inflammatory stimulus or in tissue 
of patients or animal models relevant to an inflammatory brain disorder (15-19); and (iv) a 
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list of oligodendrocyte transcription factors (20). The synaptic gene list consists of: (i) a 
manually curated list of genes of presynaptic proteins that with confirmation of proteomics 
data from isolated synapses (10,21-23), and (ii) a postsynaptic gene list based on proteomics 
data of synapses or the postsynaptic density (21-23). After combining the information from 
above mentioned resources into three lists with cell type-enriched genes, the lists were further 
curated by removing genes that were present in more than one of these gene lists, or that were 
reported to be highly expressed in neurons. The final lists consisted of 1,395 
oligodendrocytic, 1,688 astrocytic, 239 microglial and 914 synaptic genes. 
 
The genes from each of the glial gene lists (astrocytic, oligodendrocytic, microglial) were 
categorized into functional gene sets based on Gene Ontology (GO) biological process 
annotations (9). Due to the hierarchical structure of GO, gene sets can be related and can 
contain overlapping genes. Supplemental Table 1 shows the hierarchical structure of the 
functional gene sets. The synaptic gene list was categorized into functional gene sets based 
on ‘expert knowledge’ (10). This resulted in a total of 34 astrocytic, 29 oligodendrocytic, 19 
microglial and 18 synaptic gene sets.  
 
Statistical analysis 
Statistical analyses were performed using the in-house developed software tool JAG (Joint 
Analysis of Genetic variants) (24) for: (i) the four gene lists, (ii) the 100 gene sets, and (iii) 
the 4,236 single genes in the four gene lists. JAG performs two types of statistical tests: the 
self-contained test and the competitive test. All P-values in this study were calculated using 
JAG. For each GWAS dataset (Table 1), SNPs were assigned to genes if located between the 
transcription start and stop site of the respective gene, based on NCBI human assembly build 
37.3 and dbSNP release 135. Either 10 (for the Finnish and the German datasets) or 15 
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principal components (for the Dutch datasets) were used to correct for population 
stratification.  
 
Self-contained P-values (PSC) were calculated for the four gene lists, the 100 gene sets and for 
4,236 single genes using at least 15,000 permutations of the case-control status (at α = 0.05). 
The PSC-values were calculated separately for each GWAS dataset, and then combined using 
Stouffer’s Z-score method (25), weighted by the square root of the sample size. Bonferroni 
correction was used to account for multiple testing, correcting each gene set PSC-value for the 
number of gene sets in each of the four gene lists. Hence the PSC-values of the astrocytic, 
oligodendrocytic, microglial, and synaptic gene sets were corrected for 34, 29, 19 and 18 
tests, respectively.  
 
A competitive test was performed for each of the four gene lists and for each of the 100 gene 
sets that was significant (at α = 0.05) on the self-contained test. The competitive test 
calculates PSC-values for 150 random gene sets containing the same number of genes as the 
original gene list or gene set, and calculates the competitive P-value (PCOMP) as the proportion 
of random gene sets with a lower PSC-value. For gene sets found to be significant in the 
competitive test (at α = 0.05), the contribution of each gene was calculated as the drop in PSC-
value when all SNPs from that gene were removed from the analysis. 
 
The self-contained test in JAG tests the null hypothesis that a set of genes is not associated 
with migraine, while the competitive test provides insight into whether a set of genes is more 
strongly associated to migraine than other comparably-sized sets of genes. For polygenic 
traits, self-contained tests are likely to show a significant P-value, simply due to the fact that 
a gene set contains many genes. Competitive tests control for the polygenic nature of a trait 
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by evaluating the association of a gene set relative to other gene sets. We thus only interpret 
the results of the competitive test. 
 
Results 
Association analysis of the four gene lists with migraine 
We performed a gene set analysis using migraine GWAS data of 4,954 migraine patients 
(2,652 patients with migraine with aura and 2,302 patients with migraine without aura) and 
13,390 controls to further explore the involvement of glial and synaptic genes in migraine 
pathophysiology. First, we conducted an overall analysis for the four gene lists, i.e. the three 
glial gene lists (astrocyte, oligodendrocyte and microglia) and the synaptic gene list (Table 
2). A significant association (PSC and PCOMP < 0.05) was found for oligodendrocyte-related 
genes with migraine, as well as with migraine with aura and migraine without aura, 
separately (PCOMP = < 0.001, 0.040 and 0.033, respectively). No significant associations were 
found for the astrocytic, microglial and synaptic gene lists.  
 
Association analysis of functional gene sets with migraine 
Next, we studied specific functional gene sets that were defined within the four gene lists 
(Supplemental Table 1). Significant associations (PSC and PCOMP < 0.05) with migraine were 
found for three astrocytic functional gene sets (“Protein transport”, “Cell proliferation” and 
“Miscellaneous”) and three oligodendrocyte functional gene sets (“Protein modification”, 
“Signal transduction” and “Miscellaneous”) (Table 3; Supplemental Table 1). Associations 
with functional gene sets were also calculated for migraine with and migraine without aura 
separately. Two functional gene sets showed a significant association with migraine with aura 
(the astrocytic gene set “Cell proliferation” and the oligodendrocytic gene set 
“Miscellaneous”) and two gene sets showed association with migraine without aura (the 
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astrocytic gene set “Protein transport” and the oligodendrocytic gene set “Signal 
transduction”) (Table 3). Interestingly, no overlap was found between functional gene sets 
that associated with migraine with aura and those that were associated with migraine without 
aura. 
 
Gene-based analysis 
To understand whether the identified association of the functional gene sets with migraine 
was due to single genes or the gene set as a whole, a gene-based analysis was carried out. The 
association signal of the astrocytic gene sets “Protein transport” and “Cell proliferation” was 
mainly explained by the effect of GLI3 (Supplemental Table 2). The associations of the other 
gene sets were based on a joint effect of the genes in the set (Supplemental Table 2). 
 
Discussion  
We performed a gene set analysis using glial and synaptic gene sets (9,10) combined with 
data of the two clinic-based migraine GWA studies (2,5). The gene set analysis for the total 
oligodendrocyte gene list showed significant association with migraine. This suggests that in 
addition to neuronal dysfunction also oligodendrocytic dysfunction seem to play a possibly 
modulating role in migraine pathophysiology. A role for oligodendrocytes in migraine has 
not yet been proposed. Studies have shown that oligodendrocytes communicate actively with 
neurons, probably to regulate their energy supply - and thereby their activity - or to stimulate 
their myelination (26,27). By modulating neuronal excitatory signaling, oligodendrocytes 
may play a role in migraine pathophysiology. Of note, a recent study identified myelin 
abnormalities in trigeminal nerves from migraine patients (28). Sensitization of the trigeminal 
system and subsequent abnormal processing of pain signals is likely to play a causal role in 
generation of migraine headache (29).  
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Subsequently, we studied the 100functional gene sets within the glial and synaptic gene lists, 
and found that several astrocytic and oligodendrocytic gene sets were associated with 
migraine. Astrocyte dysfunction has already been implicated in migraine. For instance, the 
ATP1A2 protein, which is expressed in astrocytes in adults, is mutated in familial hemiplegic 
migraine type 2 (30), various sporadic hemiplegic migraine patients (31), and in two families 
with clustering of common migraine (32). Moreover, astrocytes have been shown to play a 
role in cortical spreading depression, the neurophysiological correlate of the migraine aura 
(33). For some of the astrocyte gene sets, the associations were mainly driven by the gene 
GLI3, for which the predominant expression in astrocytes (9) was recently confirmed by 
Zhang et al. 2014 (34). GLI3 is involved in brain development, specifically the proliferation 
and cell fate specification of neural progenitors (35-37), and astrocyte function (37). Several 
migraine GWAS top hits pinpointed genes (i.e. MEF2D, ASTN2, PRDM16, PHACTR1 and 
TGFBR2) that are involved in brain development as well (38). Notably, GLI3 was recently 
shown to be differentially expressed in the cortex of two familial hemiplegic migraine type 1 
mouse models (39), further supporting a relation between this gene and migraine 
pathophysiology.  
 
A combined effect of all genes was observed for several astrocytic and oligodendrocytic gene 
sets. The oligodendrocytic gene sets “Signal transduction” and “Protein modification” might 
relate to the active role that oligodendrocytes can play in the regulation of the energy supply 
and possibly the activity of neurons (26,27). Interestingly, the “Miscellaneous” gene sets 
contain a large percentage of membrane-associated and transmembrane genes. Furthermore, 
PHACTR1, one of the migraine GWAS top hits, contributes together with PHACTR3 strongly 
to the association of the oligodendrocytic “Miscellaneous” gene set. Both genes regulate 
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protein phosphatase 1, a protein with a main role in synaptic plasticity (40). This indicates 
that the genes from the “Miscellaneous” gene sets may have related functions involved in 
migraine that are not identified yet when classifying genes into GO-based functional 
categories.  
 
There are limitations of the study design used. Foremost, the validity of GO to classify glia 
cell and synaptic genes into gene sets based on their function is inherently limited to current, 
surely incomplete, knowledge about gene functions as well as the incomplete use of this 
knowledge within GO. As a consequence, for instance, the size of the “Miscellaneous” gene 
sets is quite large. By using well-defined, expert-curated gene sets (mostly based on 
experimental data), we tried to do our utmost to minimize this limitation. Expected 
improvements and expansions of GO and similar public databases will increase the size and 
specificity of functional gene sets for future studies. A second limitation of this study is that 
by limiting our analyses to glia cell and synaptic gene sets, we potentially missed associations 
with other cell types, such as those involved in the brain vasculature, that have been 
implicated in migraine (41). The reason for this omission is that we intended to increase the 
reliability of the results by using only well-defined, expert-curated gene sets, which are not 
available for other cell types.  
 
Our separate analyses for migraine with and without aura showed different results. Of all 
functional gene sets that associated with migraine, none associated with both subtypes. This 
limited overlap in genetic risk for both migraine subtypes was previously observed in the 
migraine GWA studies. For example, the only identified migraine with aura GWAS locus 
that contains the MTDH gene (2) showed no signal of association in the migraine without 
aura GWAS (3,5). This suggest that despite the clinical overlap, different and additional 
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genes may play a role and may explain the aura phenomenon. Of note, the diagnosis of 
migraine with aura patients is based on ICHD-IIIbeta guidelines and includes patients with 
migraine with aura that either experience an aura in all of their attacks and patients that 
experience also attacks without an aura (1). Differences between migraine with aura and 
migraine without aura identified in the current study may even be more pronounced when 
including only migraine with aura patients that experience an aura before each attack. At the 
moment, we lack genotyping data of a sufficiently large number of patients that exclusively 
have migraine with aura attacks to perform such an analysis.  
 
For a similar reason we did not perform our analyses separately for males and females. The 
low percentage of males in our cohorts (ranging from 13% in the German migraine without 
aura cohort and 20% in the Finnish migraine with aura cohort) (Table 1), the male subgroup 
would be underpowered for our gene set analyses. It is uncertain whether such a gender 
analysis would have given different insights as: (i) heterogeneity analyses reported in the 
migraine GWAS meta-analysis (3) showed very low heterogeneity between female and male 
subgroups, and (ii) a SNP effect concordance analysis of migraine GWAS data (42) showed 
very high SNP concordance of GWAS signal between male and female subgroups.  
 
In conclusion, our results indicate that astrocyte- and oligodendrocyte-related gene sets may 
play a role in migraine susceptibility, especially those involved in protein modification and 
signal transduction. Furthermore, our results suggest that migraine with and migraine without 
aura may be conferred by – at least partly – different genetic factors.  
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Article highlights 
- Gene-based analysis of GWAS data indicated that astrocytes and oligodendrocytes are 
genetically involved in migraine pathophysiology; 
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- The association of functional gene sets differed between migraine with aura and migraine 
without aura, indicating that both migraine types – at least in part – have a different 
genetic background. 
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Supplemental Table 1: Association of all functional gene sets with migraine, migraine with 
and migraine without aura. 
Supplemental Table 2: Gene-based analysis showing the contribution to the total association 
signal with migraine for each gene in the gene set.  
Supplemental Table 3: Gene-based analysis showing the contribution to the total association 
signal with migraine with aura for each gene in the gene set.  
Supplemental Table 4: Gene-based analysis showing the contribution to the total association 
signal with migraine without aura for each gene in the gene set. 
